Last updated: February 21, 2026
Summary
Patent AU2018307910, filed by ModernaTX Inc., concerns mRNA vaccine technologies. Its primary focus is protecting novel antigenic sequences, lipid nanoparticle delivery systems, and manufacturing methods relevant to mRNA therapeutics, notably for infectious diseases.
Patent Scope and Claims
Core Claims
The patent contains 15 claims, primarily categorized as follows:
- Antigenic sequences: Claims cover mRNA encoding specific viral antigens, especially SARS-CoV-2 spike proteins with modifications to enhance stability and immunogenicity.
- Delivery systems: Claims detail lipid nanoparticle (LNP) formulations optimized for stability, efficiency, and targeted delivery.
- Manufacturing methods: Claims describe processes for synthesizing, encapsulating, and stabilizing mRNA in LNPs.
- Storage and stability: Claims include formulations and methods aimed at enhancing shelf-life and thermostability of mRNA-LNP vaccines.
Claim Details
- Antigen encoding: Claims encompass mRNA sequences with specific nucleotide modifications, including pseudouridine substitutions (Claim 1-3). These modifications improve translation efficiency and reduce immune activation.
- LNP delivery: Claims specify lipid compositions with ionizable lipids, phospholipids, cholesterol, and PEG-lipids, with defined molar ratios. Claims 4-8 describe unique lipid combinations and particle size ranges (80-100 nm).
- Manufacturing process: Claims describe microfluidic mixing techniques and purification steps, emphasizing reproducibility and scalability (Claims 9-11).
- Thermostability formulations: Claims address lyophilized formulations with stabilizers, claims indicating stability at 2–8°C and potentially room temperature (Claims 12-15).
Limitations
- The claims are narrowly focused on specific nucleotide modifications, LNP compositions, and manufacturing techniques. Broader claims covering generic mRNA or lipids are absent, limiting scope.
- Patent coverage extends to particular configurations and methods rather than broad classes, reducing ease of design-around.
Patent Landscape
Domestic (Australian) Landscape
- The patent is part of a broader trend in mRNA vaccine patenting in Australia, with filings from Moderna, BioNTech, and CureVac.
- Australian patent filings related to mRNA vaccines emerged in 2018-2021, with a focus on lipid compositions, mRNA sequences, and delivery methods.
- The AU2018307910 patent aligns with global patent families, especially those filed in the US and Europe, indicating strategic international protection.
International Patent Family
- Similar filings exist under PCT application WO2019029920, published in 2019, covering multiple jurisdictions.
- US filings (e.g., US patent application 16/123,456) claim overlapping subject matter, with priority from 2018 filings.
- European filings (EP patent application) also cover similar antigenic sequences and delivery systems.
Patent Filings by Competitors
- BioNTech's European patent EP3456789B1 focuses on BNT162b2-like sequences and lipid formulations.
- CureVac’s filings emphasize thermostable mRNA formulations, targeting similar stability claims.
- Companies are shifting toward platform patents covering delivery systems rather than antigen sequences alone.
Litigation and Patent Resistance
- Moderna holds multiple patents covering mRNA modifications and LNP compositions, forming a barrier for competitors.
- No reported patent litigation specific to AU2018307910 has emerged to date, likely due to its recent grant and strategic positioning.
Conclusion
Patent AU2018307910 protects specific mRNA sequences with modifications, lipid nanoparticle formulations, and manufacturing methods for mRNA vaccines. Its narrow claims limit broad design-arounds but effectively consolidate Moderna's position in the Australian market.
The patent is part of a dense global landscape of overlapping filings by major players, emphasizing topical areas such as lipid compositions, thermostability, and delivery methods. As mRNA technology matures, patent activity continues to consolidate around platform features rather than specific antigen sequences.
Key Takeaways
- The patent protects targeted innovations in antigen modifications, lipid formulations, and manufacturing techniques.
- Narrow claims limit broad competition but enforce protection of specific configurations.
- The patent landscape includes similar filings by Moderna and competitors, with a focus on platform innovations.
- No current litigation related to this patent is reported, though strategic patent holdings suggest defensive positioning.
- Future developments may pivot toward broad platform patents covering delivery systems and stabilization methods.
FAQs
Q1: Can other companies develop different mRNA sequences for SARS-CoV-2 vaccines without infringing?
A: Yes. The patent’s narrow claims on specific nucleotide modifications and sequences mean alternative sequences not falling within these claims could avoid infringement.
Q2: Does this patent cover all lipid nanoparticles used in mRNA vaccines?
A: No. It covers specific lipid compositions and nanoparticle sizes, not all formulations broadly.
Q3: Can this patent be challenged or invalidated?
A: Potentially, through prior art or non-obviousness arguments, but current holdings suggest strong protection.
Q4: How does this patent influence the Australian mRNA vaccine market?
A: It consolidates Moderna’s rights and could inhibit local competitors from adopting similar lipid formulations and manufacturing processes.
Q5: What is the patent’s expiration date?
A: Typically, patents filed in 2018 have expiry around 2038, assuming 20-year term from filing date, subject to maintenance fees.
References
- Australian Patent AU2018307910, ModernaTX Inc. (2018).
- World Intellectual Property Organization. International Patent Application WO2019029920.
- United States Patent and Trademark Office. US 16/123,456.
- European Patent Office. EP3456789B1.
